Enhanced cytotoxicity of bleomycin and cisplatin after electroporation in murine colorectal carcinoma cells

Radiology and Oncology

Volumn 43, Issue 4, 2009, Pages 264-273

  Todorovic, Vesna ^a   Sersa, Gregor ^a   Flisar, Karel ^c   Cemazar, Maja ^a,b  

^a UNIVERSITY OF PRIMORSKA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bleomycin; Cisplatin; Colorectal carcinoma; Electrochemotherapy; Electroporation

Indexed keywords

BLEOMYCIN; CASPASE 3; CASPASE 7; CISPLATIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ELECTROCHEMOTHERAPY; ENZYME ACTIVITY; NONHUMAN;

EID: 71049128234     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-009-0037-5     Document Type: Article

References (26)

1. Sersa G, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy of tumours. Radiol Oncol 2006; 40: 163-174
2. Teissie J, Escoffre JM, Rols MP, Golzio M. Time dependence of electric field effects on cell membranes. A review for a critical selection of pulse duration for therapeutical applications. Radiol Oncol 2008; 42: 196-206.
3. Cemazar M, Sersa G, Miklavcic D. Electrochemotherapy with cisplatin in the treatment of tumour cells resistant to cisplatin. Anticancer Res 1998; 18: 4463-4466
4. Orlowski S, Belehradek J Jr, Paoletti, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727-4733
5. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000; 11: 201-208
6. Cemazar M, Miklavcic D, Mir LM, Belehradek J Jr, Bonnay M, Fourcault D, et al. Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model. Eur J Cancer 2001; 37: 1166-1172
7. Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. EJC Suppl 2006; 4: 52-59
8. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13.
9. Kuriyama S, Matsumoto M, Mitoro A, Tsujinoue H, Nakatani T, Fukui H, et al. Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model. Dig Dis Sci 2000; 45: 1568-1577
10. Kuriyama S, Tsujinoue H, Toyokawa Y, Mitoro A, Nakatani T, Yoshiji H, et al. A potential approach for electrochemotherapy against colorectal carcinoma using a clinically available alternating current system with bipolar snare in a mouse model. Scand J Gastroenterol 2001; 36: 297-302.
11. Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumour cells to bleomycin as an indicator of tumour response to electrochemotherapy. Jpn J Cancer Res 1998; 45: 328-333
12. Kranjc S, Cemazar M, Grosel A, Pipan Z, Sersa G. Effect of electroporation on radiosensitization with cisplatin in two cell lines with different chemo- and radiosensitivity. Radiol Oncol 2003; 37: 101-107
13. Kambe M, Arita D, Kikuchi H, Funato T, Tezuka F, Gamo M, et al. Enhancement of the efficacy of anticancer drugs with electroporation: successful electrochemotherapy against gastric cancer cell lines in vivo and in vitro. Int J Clin Oncol 1997; 2: 111-117
14. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. EJSO 2008; 34: 232-240
15. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003; 10: 257-266
16. Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.
17. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Brit J Cancer 2001; 84: 1272-1279
18. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005; 5: 102-112
19. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279
20. Tounekti O, Pron G, Belehradek J, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993; 53: 5462-5469
21. Gonzales VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-663
22. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320
23. Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM. In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Brit J Cancer 2003; 88: 1763-1771
24. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B. DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 2008; 15: 555-566
25. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Cancer 2008; 9: 231-241
26. Sadadcharam M, Soden DM, O'Sullivan GC. Electrochemotherapy: An emerging cancer treat